Message #25 From:
Stock News Bot Date: December 11, 2006 09:15:00 AM
PLRS News Dutton Associates Announces Investment Opinion: Pluristem Life Sciences Speculative Buy Rating in Update Coverage by Dutton Associates
EL DORADO HILLS, Calif.--(BUSINESS WIRE)--Dutton Associates updates its coverage of Pluristem Life Sciences
(OTCBB:PLRS), maintaining a speculative buy rating and a $.06 price
target. The 14-page report by Dutton senior analyst William R. Prather,
R.Ph., M.D. is available at www.jmdutton.com
as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and
other leading financial portals.
Pluristem’s PluriX™
technology has the potential to enable umbilical cord blood to become an
alternative to bone marrow transplant (BMT), eliminating the current BMT
search and match process. Since we initiated coverage on the Company in
September 2006, we believe Pluristem has made significant strides with
its technology, documented, in part, by the fact that they were invited
to present data at the American Society of Hematology (ASH) on December
10, 2006, in Orlando, Florida. We also believe the Company is
negotiating collaborations with other companies and scientific entities
for using PLX cells in addressing a variety of ailments, such as stroke
and limb ischemia (lack of blood supply). This is because the stem cells
expanded in Pluristem’s PluriX reactor are
multipotent and potentially able to differentiate into a variety of
other cells, tissues and organs. Additionally, we believe these cells
are also immune-privileged. We believe that at Pluristem’s
current market value of approximately $3.8 million, speculative,
risk-tolerant, patient investors could potentially see a significant
upside relative to a downside of losing their entire investment. We
believe this is true despite the fact that Pluristem will need to raise
additional capital in the spring of 2007. One only need examine
comparable companies such as Osiris Therapeutics, Inc. (NASDAQ:OSRI) and
ViaCell (NASDAQ:VIAC), which have an average value of approximately $375
million, to see the potential upside for Pluristem.
About Dutton Associates
Dutton Associates is one of the largest independent investment research
firms in the U.S. Its 31 senior analysts are primarily CFAs, and have
expertise in many industries. Dutton Associates provides continuing
analyst coverage of over 140 enrolled companies, and its research,
estimates, and ratings are carried in all the major databases serving
institutions and online investors.
The cost of enrollment in our one-year continuing research program is US
$39,500 prepaid for 4 Research Reports, typically published quarterly,
and requisite Research Notes. Dutton Associates received $20,000 from
the Company for 2 Research Reports with coverage commencing on
9/06/2006. We do not accept payment of our fees in company stock. Our
principals and analysts are prohibited from owning or trading in
securities of covered companies. The views expressed in this research
report accurately reflect the analyst's personal views about the subject
securities or issuer. Neither the analyst's compensation nor the
compensation received by us is in any way related to the specific
ratings or views contained in this research report or note. Please read
full disclosures and analyst background at www.jmdutton.com
before investing.
